Yerushalmi Y, Shem-Tov N, Danylesko I, Canaani J, Avigdor A, Yerushalmi R, et al. Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation. Haematologica 2023;108:1782–92.

Article  PubMed  Google Scholar 

Avenoso D, Mehra V, Slonim LB, de Farias M, Alshehri H, Bouziana S, et al. Myeloablative dose of busulfan and fludarabine combined with in vivo T cell depletion is safe and effective conditioning for acute myeloid leukemia and myelodysplastic syndrome patients. Transplant Cell Ther. 2023;29:698.e1-698.e6.

Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012;119:1599–606. 

Article  CAS  PubMed  Google Scholar 

Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916–24.

Article  PubMed  PubMed Central  Google Scholar 

Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non- inferiority, phase 3 trial. Lancet Haematol. 2020;7:e28–39.

Article  PubMed  Google Scholar 

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022;140:1345–77.

Article  PubMed  Google Scholar 

Shimoni A, Labopin M, Finke J, Ciceri F, Deconinck E, Kröger N, et al. Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. Blood Cancer J. 2019;9:88.

Article  PubMed  PubMed Central  Google Scholar 

Zuanelli Brambilla C, Lobaugh SM, Ruiz JD, Dahi PB, Goldberg AD, Young JW. t al. Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular therapy. Transplant Cell Ther 2021;27:771.e1–771.e10.

Article  CAS  PubMed  Google Scholar 

Yadav C, Damodar S, Bhargava R, Haridas NK, Jaishetwas GS, Paul M, et al. Fludrabine treosulfan conditioning regimen appears safe and effective in patients with acute myeloid leukemia(AML) and myelodysplastic syndrome (MDS) undergoing allogenic hematopoietic stem cell transplantation (HSCT). Blood. 2022;140:12816–8.

Article  Google Scholar 

Rehman MEU, Suheb MK, Umar H, Naaz F, Shah Z, Khan Z, et al. Busulfan versus treosulfan conditioning for acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. JCO. 2023;41:e19032.

Article  Google Scholar 

Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson KMO, et al. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024. https://doi.org/10.1038/s41409-024-02269-4. Epub ahead of print.

Gavriilaki E, Labopin M, Sakellari I, Salmenniemi U, Yakoub-Agha I, Potter V, et al. Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Bone Marrow Transpl. 2022;57:1803–9.

Article  CAS  Google Scholar 

Rotstein, M. 2nd stem cell transplants funding re-instated by NHS England - MDS Patients Support Group. MDS UK Patient Support Group. 2017. https://mdspatientsupport.org.uk/second-stem-cell-transplants/.

Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, et al. Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the Grupo Español de Trasplante Hematopoyetico. Biol Blood Marrow Transplant. 2016;22:584–8. https://doi.org/10.1016/j.bbmt.2015.11.012.

Article  PubMed  Google Scholar